Blinatumomab (Blincyto)

From - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: Bi-specific T-cell engager (BiTE) antibody that targets CD19 (expressed on B cells) and CD3 (expressed on T cells).[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Toxicity management

Diseases for which it is used

Patient drug information

History of changes in FDA indication

History of changes in EMA indication

  • 2015-11-23: Initial authorization

History of changes in Health Canada indication

  • 2015-12-22: Initial notice of compliance with conditions
  • 2017-04-28: Notice of compliance with conditions for the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor ALL.
  • 2017-11-16: Conditions were met
  • 2019-12-19: Notice of compliance with conditions for the treatment of patients with Philadelphia chromosome-negative CD19 positive B-precursor acute lymphoblastic leukemia (ALL) in first or second hematologic complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.

Also known as

  • Code names: AMG 103, MEDI538, MT103
  • Brand name: Blincyto